A 2014 review assessed MAT with methadone or buprenorphine-containing agents.

Interventions of Interest:

  • Buprenorphine (Subutex®, Reckitt Benckiser Pharmaceuticals Inc.
  • Buprenorphine and naloxone (Suboxone®, Indivior Inc.)
  • Dose-tapering strategies for methadone or Suboxone, with or without naltrexone (Revia®, Duramed Pharmaceuticals, Inc.
  • Naltrexone (Vivitrol®, Alkermes, Inc.)
  • Use of naltrexone alone without prior stabilization on methadone or buprenorphine
  • Drug-free opioid withdrawal management

For questions or additional information, please contact info@icer.org


Final Documents

Below you will find the final documents from the assessment review process: